Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients.
Recommended Citation
Bandini M, Preisser F, Nazzani S, Marchioni M, Tian Z, Fossati N, Gandaglia G, Gallina A, Abdollah F, Shariat SF, Montorsi F, Saad F, Tilki D, Briganti A, and Karakiewicz PI. Contemporary trends and survival outcomes after aborted radical prostatectomy in lymph node metastatic prostate cancer patients. Eur Urol Focus 2018; 5(3):381-388.
Document Type
Article
Publication Date
5-1-2019
Publication Title
Eur Urol Focus
Abstract
BACKGROUND: Aborted radical prostatectomy (aRP) in lymph node (LN) metastatic (pN1) prostate cancer (PCa) patients showed worse survival in European patients. Contemporary rates of aRP are unknown in North America.
OBJECTIVE: To examine the rate of aRP and its effect on cancer-specific mortality (CSM) in contemporary North American patients.
DESIGN, SETTING, AND PARTICIPANTS:
Within the Surveillance Epidemiology and End Results database (2004-2014), we identified 3719 pN1 PCa patients.
INTERVENTION: RP.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Incidence proportion and median survival of LN metastatic PCa patients who underwent aRP versus completed RP (cRP). Cumulative incidence plots and competing-risks regression (CRR) models tested CSM and other-cause mortality rates according to aRP versus cRP. The effect of selected variables on CSM rate was graphically depicted using LOESS methodology. All analyses were repeated after propensity score matching.
RESULTS AND LIMITATIONS: Between 2004 and 2014, the rate of aRP decreased from 20.4% to 5.6% (p<0.001). Ten-year CSM rates were significantly higher after aRP (38.9% vs 21.6%) versus cRP (p<0.001). In multivariable CRR models, aRP yielded higher CSM (hazard ratio [HR]: 1.99) than cRP. A higher 5-yr CSM rate was recorded after aRP through the entire range of baseline prostate-specific antigen (PSA) values and in patients with up to nine LN metastases. After propensity score matching, aRP resulted in overall higher CSM (HR: 1.72). Higher CSM was recorded after aRP for PSA values up to 50ng/ml and in patients with up to seven LN metastases. Results were limited by a selection bias that applies to aRP patients.
CONCLUSIONS: Of contemporary North American patients, 5% are affected by aRP. It confers a significant survival disadvantage that applies to patients with baseline PSA values up to 50ng/ml and in those with up to seven LN metastases.
PATIENT SUMMARY: Radical prostatectomy should not be aborted in pN1 prostate cancer individuals.
PubMed ID
29366856
Volume
5
Issue
3
First Page
381
Last Page
388
